Amundi
ELVN icon

Amundi’s Enliven Therapeutics ELVN Stock Holding History

Amundi’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Sell
6,041
-895
-13% -$38K ﹤0.01% 1834
2026
Q1 		$272K Buy
+6,936
New +$192K ﹤0.01% 1778
2025
Q2 		– Sell
-23
Closed -$461 – 1821
2025
Q1 		$461 Hold
23
– – ﹤0.01% 2131
2024
Q4 		$555 Buy
+23
New +$596 ﹤0.01% 2102

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Amundi's ELVN Position: Q2 2026 in Review

Amundi reduced its Enliven Therapeutics (ELVN) stake by 13% in Q2 2026, selling an estimated $38K and leaving 6,041 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

Amundi first reported a position in ELVN in Q4 2024 and has held it in 4 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Amundi held 6,041 shares of Enliven Therapeutics worth $307K as of Q2 2026.
  • Amundi sold 895 Enliven Therapeutics shares in Q2 2026, an estimated $38K.
  • Enliven Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1834 holding.
  • Amundi first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.